Kyoung Ae Kim

US Patent:

6392053, May 21, 2002

Filed:

Dec 22, 2000

Appl. No.:

09/746059

Inventors:

Kyoung S. Kim - North Brunswick NJ
S. David Kimball - East Windsor NJ
Raj N. Misra - Hopewell NJ
Joseph E. Sundeen - Yardley PA
Rulin Zhao - Pennington NJ

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D41712

US Classification:

548185

Abstract:

The present invention relates to new, efficient processes for the preparation of 5-(2-oxazolylalkylthio)-2-arylacetylaminothiazole compounds of formula I or a pharmaceutically acceptable salt thereof, wherein: R , R , R , R , R , R , R , R and R are each independently hydrogen, alkyl, aryl or heteroaryl; R , R , R and R are each independently hydrogen, alkyl, aryl, heteroaryl, halogen, hydroxy or alkoxy; and X is CH or N, which are novel, potent inhibitors of cyclin dependent kinases (cdks). The present invention also concerns a new process for the preparation of formylarylacetates and formylarylacetic acids.

US Patent:

6414156, Jul 2, 2002

Filed:

Dec 22, 2000

Appl. No.:

09/746060

Inventors:

Kyoung S. Kim - North Brunswick NJ
S. David Kimball - East Windsor NJ
Raj N. Misra - Hopewell NJ
Mark E. Salvati - Lawrenceville NJ
Joseph E. Sundeen - Yardley PA
Rulin Zhao - Pennington NJ

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D41714

US Classification:

546209, 548185

Abstract:

The present invention relates to new, efficient processes for the preparation of 5-(2-oxazolylalkylthio)-2-azacycloalkanoylaminothiazole compounds of formula I or a pharmaceutically acceptable salt thereof, wherein: R is alkyl, aryl or heteroaryl; R , R , R , R and R are each independently hydrogen, alkyl, aryl or heteroaryl; R and R are each independently hydrogen, alkyl, aryl, heteroaryl, halogen, hydroxy or alkoxy; R is hydrogen, alkyl, aryl, heteroaryl, CONR R , COR or COOR ; R , R , R and R are each independently hydrogen, alkyl or aryl; m equals 0 to 5; and n equals 0 to 5, which are novel, potent inhibitors of cyclin dependent kinases (cdks). The present invention further concerns new key intermediate compounds, a quaternary ammonium salt of formula IIIâ and a 2-oxazolylalkyl derivative of formula IX.

US Patent:

6456850, Sep 24, 2002

Filed:

Aug 17, 1999

Appl. No.:

09/375892

Inventors:

Kyoung Kim - Bridgewater NJ
Alexandro Federico Salvarani - Edison NJ

Assignee:

Lucent Technologies Inc. - Murray Hill NJ

International Classification:

H04Q 720

US Classification:

455453, 455423, 455436

Abstract:

A method for preventing overload conditions in a communication system. The communication system performs a call load analysis and admits a subscriber requesting admission (or responding to a page) to the system based on the result of the call load analysis. The call load analysis is based on the signal to noise power ratios of all subscribers already admitted to the communication system. External jammer signals that interfere with subscriber signals thus reducing the coverage of the communication system do not affect the call load analysis. The jammer signals therefore, do not hinder an efficient use of the capacity of the communication system. A threshold value is established and such threshold value is compared to an average call load value calculated from a plurality of instantaneous call load values. When the calculated average call load value is substantially equal to or above the established threshold, no subscribers are admitted to the communication system; subscribers are admitted when the calculated average call load value is below the established threshold. Individual subscribers whose contributions to the average call load value are deemed significant (tending to cause or actually causing overload conditions) are identified and removed from the system.

US Patent:

6521759, Feb 18, 2003

Filed:

Apr 20, 2001

Appl. No.:

09/839751

Inventors:

Kyoung S. Kim - North Brunswick NJ
S. David Kimball - East Windsor NJ
David B. Rawlins - Morrisville PA
Raj N. Misra - Hopewell NJ
Michael A. Poss - Lawrenceville NJ
Kevin R. Webster - Yardley PA
John T. Hunt - Princeton NJ
Wen-Ching Han - Newtown PA

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D41712

US Classification:

548184

Abstract:

The present invention describes compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R , R , R , R , R , m and n are as defined in the specification. The compounds of formula I are protein kinase inhibitors and are useful in the treatment of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of Alzheimers disease, chemotherapy-induced alopecia, and cardiovascular disease.

US Patent:

6591110, Jul 8, 2003

Filed:

Jun 27, 2000

Appl. No.:

09/604574

Inventors:

Kyoung Il Kim - Bridgewater NJ
Alexandro Federico Salvarani - Edison NJ

Assignee:

Lucent Technologies Inc. - Murray Hill NJ

International Classification:

H04Q 720

US Classification:

455453, 455436, 455423, 455 671, 455454, 455424, 455 673, 370332, 370333, 375224, 375227

Abstract:

A method for detecting and calculating the contribution by external jammer signals to the total power received by a reverse link of a communication system. The total received power for a reverse link is measured. Calculations of load estimates based on power rise due to background noise and total E /N are performed. The contribution of external jammer signals to the total power received is calculated from the load estimates. The ability to calculate the power level of external jammer signals for a certain reverse link allows a service provider to more efficiently use the capacity of the reverse link. An average of the calculated external jammer power level can be calculated over a period of time defined by the service provider of the communication system.

US Patent:

6613911, Sep 2, 2003

Filed:

Feb 5, 2002

Appl. No.:

10/067723

Inventors:

Kyoung S. Kim - North Brunswick NJ
S. David Kimball - East Windsor NJ
Raj N. Misra - Hopewell NJ
Joseph E. Sundeen - Yardley PA
Rulin Zhao - Pennington NJ

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D41712

US Classification:

548185

Abstract:

The present invention relates to new, efficient processes for the preparation of 5-(2-oxazolylalkylthio)-2-arylacetylaminothiazole compounds of formula I: or a pharmnaceutically acceptable salt thereof, wherein: R , R , R , R , R , R , R , R and R are each independently hydrogen, alkyl, aryl or heteroaryl; R , R , R and R are each independently hydrogen, alkyl, aryl, heteroaryl, halogen, hydroxy or alkoxy; and X is CH or N, which are novel, potent inhibitors of cyclin dependent kinases (cdks). The present invention also concerns a new process for the preparation of formylarylacetates and formylarylacetic acids.

US Patent:

6639074, Oct 28, 2003

Filed:

Mar 18, 2002

Appl. No.:

10/100129

Inventors:

Kyoung S. Kim - North Brunswick NJ
S. David Kimball - East Windsor NJ
Raj N. Misra - Hopewell NJ
Mark E. Salvati - Lawrenceville NJ
Joseph E. Sundeen - Yardley PA
Rulin Zhao - Pennington NJ

Assignee:

Bristol Myers Squibb Company - Princeton NJ

International Classification:

C07D47100

US Classification:

546 63

Abstract:

The present invention relates to new, efficient processes for the preparation of 5-(2-oxazolylalkylthio)-2-azacycloalkanoylaminothiazole compounds of formula I or a pharmaceutically acceptable salt thereof, wherein: R is alkyl, aryl or heteroaryl; R , R , R , R and R are each independently hydrogen, alkyl, aryl or heteroaryl; R and R are each independently hydrogen, alkyl, aryl, heteroaryl, halogen, hydroxy or alkoxy; R is hydrogen, alkyl, aryl, heteroaryl, CONR R , COR or COOR ; R , R , R and R are each independently hydrogen, alkyl or aryl; m equals 0 to 5; and n equals 0 to 5, which are novel, potent inhibitors of cyclin dependent kinases (cdks). The present invention further concerns new key intermediate compounds, a quaternary ammonium salt of formula IIIâ and a 2-oxazolylalkyl derivative of formula IX.

US Patent:

6897321, May 24, 2005

Filed:

Aug 12, 2003

Appl. No.:

10/639272

Inventors:

Kyoung S. Kim - North Brunswick NJ, US
S. David Kimball - East Windsor NJ, US
Raj N. Misra - Hopewell NJ, US
Mark E. Salvati - Lawrenceville NJ, US
Joseph E. Sundeen - Yardley PA, US
Rulin Zhao - Pennington NJ, US

Assignee:

Briston Myers Squibb Company - Princeton NJ

International Classification:

C07D263/30

US Classification:

548235

Abstract:

The present invention relates to new, efficient processes for the preparation of 5-(-2-oxyazolylalkylthio)-2-azacycloalkanoylaminothiazole compounds of formula I or a pharmaceutically acceptable salt thereof, wherein:.